2021年第82回応用物理学会秋季学術講演会

講演情報

一般セッション(口頭講演)

12 有機分子・バイオエレクトロニクス » 12.7 医用工学・バイオチップ

[10a-S402-1~13] 12.7 医用工学・バイオチップ

2021年9月10日(金) 09:00 〜 12:30 S402 (口頭)

高橋 一浩(豊橋技科大)、徳田 崇(東工大)、横式 康史(東工大)

09:30 〜 09:45

[10a-S402-3] Monitoring T-cell Exhaustion and Immune Response at Single Cell Resolution

Jonathan Briones1,3、Wilfred Espulgar1,2、Shohei Koyama1、Hyota Takamatsu1、Eiichi Tamiya2,3、Masato Saito1,3 (1.Osaka University、2.AIST PhotoBIO-OIL、3.ISIR, Osaka Univ.)

キーワード:Microfluidics, Single Cell Analysis, Immunotherapy

Single-cell analysis platforms, particularly microfluidic platforms, have shown significant advantages over bulk measurements to achieve a deeper understanding of the immune mechanisms. For instance, single cell evaluation of the immune cell activities can reveal information like a state of dysfunction or T-cell exhaustion, which could have been missed by the averaging of population results in conventional bulk methods. Since programmed death receptor-1 (PD-1) expression on the cell’s surface is correlated with the exhaustion state, profiling PD-1 expressing cells and monitoring its immune activity like Granzyme B (GrB) production, is important to clinicians and researchers. Also, immune response to cancer treatment drugs (i.e. Nivolumab) can be monitored by profiling the cells with antibody blocked PD-1 receptors. Here, the profile generated can provide a wider view into the patient’s potential response to the treatment and pinpoint special cells with overexpression.
In this work, we developed a high-throughput valve-based microfluidic platform for single cell GrB activity assay. The GrB production per cell was measured fluorometrically with the cleavage of a peptide substrate containing the GrB recognition sequence (Ac-IEPD-AFC) and AFC label. Immunostaining was performed to human PBMC cells (healthy and patient) to identify cell type, PD-1 expression, and binding of IgG4 antibody. The cells’ activity profiles were generated to reveal information on the cell state, its GrB activity, and response to immunotherapy.